Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 19, 2007 Brian Orelli	Trimeris Reaches a Plateau Drug developer Trimeris needs to push another drug out of its pipeline because sales of its only drug, Fuzeon, appear to be hitting the wall. Investors, take note.
The Motley Fool March 19, 2007 Brian Lawler	Trimeris Gets Trimmed Shares of the drug developer are down after a management shakeup. With shares trading near their 52-week lows amid all the pessimism, now is a good time for less-risk adverse investors to buy in.
The Motley Fool April 23, 2004 Charly Travers	A Difficult Drug Launch Investors expected a lot from Fuzeon, Trimeris' HIV drug therapy. However, anticipated sales for the biotechnology company didn't materialize.
The Motley Fool April 23, 2007 Brian Lawler	Trimeris Isn't Tumbling Trimeris announces first-quarter sales numbers for its HIV drug Fuzeon. Shares of the company were up 25% last week after it reported stronger-than-expected sales of the fusion inhibitor.
The Motley Fool November 30, 2007 Brian Lawler	Not What Trimeris Needs Small biopharma Trimeris revealed that it and partner Roche were being sued for patent infringement by Novartis over Trimeris' only marketed compound, Fuzeon.
The Motley Fool October 17, 2006 Brian Lawler	Roche Rocks The Swiss pharma has a stable of hot brands and lots of promise in the pipeline. Investors, this may be a pharmaceutical worth looking at.
The Motley Fool January 30, 2008 Brian Lawler	The Competition Bites Trimeris Rivals lead to lower sales of the small specialty pharmaceutical's only marketed drug.
The Motley Fool August 15, 2007 Brian Lawler	Call for Change at Trimeris A shareholder group criticizes tiny Trimeris about its spending on research. In an SEC filing, HealthCor, which owns 15% of the outstanding shares, called for the pharmaceutical company to cut back on its research and development expenses and to explore selling the company.
The Motley Fool November 16, 2007 Brian Lawler	Trimeris Gets a Cleanup Hitter Tiny drug developer Trimeris announces that it has finally found a permanent CEO to help get itself in order following the resignation of its former leader a year ago.
The Motley Fool January 31, 2008 Brian Lawler	Don't Forget Roche Roche, the largest biopharma, by market capitalization, had a terrific 2007. Since it is not publicly listed on the major U.S. stock exchanges, the company never gets its fair share of attention.
Chemistry World August 29, 2014 Sarah Houlton	Roche to buy InterMune for respiratory boost Roche is to acquire InterMune in a deal worth $8.3 billion.
The Motley Fool July 13, 2004 Charly Travers	With Pfizer Drug, HIV Retreats Pfizer's newest HIV treatment shows promise in a demanding market.
BusinessWeek November 25, 2009 Arlene Weintraub	Can Roche Leave Genentech Alone? Now that Roche has acquired the biotech superstar, success will depend on keeping some distance.
The Motley Fool May 18, 2011 Brian Orelli	If You Can't Beat 'Em, Use 'Em to Beat Your New Rival Merck is supposed to be a bitter rival to Roche in the hepatitis C space. Instead, it's extending the hand of friendship.
The Motley Fool May 28, 2010 Brian Orelli	Innovators Will Rule the Economic Crisis Roche's CEO says two areas of health care can prosper. I agree.
The Motley Fool March 15, 2004 Ben McClure	More R&D, Please Big tech players up the research and development ante.
The Motley Fool July 21, 2008 Brian Lawler	Roche Wants to Buy Genentech -- Again In what could become one of the biggest biotech deals ever, Roche announces that it is offering to pay $43.7 billion for the remaining Genentech shares it doesn't already own.
Chemistry World March 13, 2009 Sarah Houlton	Mega mergers sweep pharma industry Just six weeks after Pfizer agreed to buy Wyeth, US pharma companies Merck & Co. and Schering-Plough announced they are to merge.
The Motley Fool August 27, 2010 Brian Orelli	Down 35%! This Just Shouldn't Happen Someone's to blame and it isn't ImmunoGen.
The Motley Fool August 14, 2008 Brian Lawler	Genentech Asks Roche to Pay Up In one of the more friendly spurnings of a buyout offer in recent months, Genentech calls Roche's $89-per-share buyout offer too low, and very nicely implies that Roche should up its bid.
The Motley Fool May 25, 2005 Tom Taulli	Genentech's Vision Thing Genentech has been on fire. Now the challenge will be to manage the growth. Investors, take note.
The Motley Fool July 20, 2005 Stephen D. Simpson	Two Ways to Play Roche Trying to track Roche is a pain, so investors might want to think about Genentech instead.
The Motley Fool January 7, 2004 Alyce Lomax	Try Again, Trimeris Headline skimmers, beware. When a company plays "hide and seek," and the object that's hiding is a piece of bad news, it's no laughing matter to investors. Trimeris got busted Monday following market close after it issued what was considered a rather deceptive press release.
The Motley Fool June 3, 2011 Brian Orelli	Tag-Teaming Melanoma for Fun and Profit Bristol-Myers Squibb and Roche hook up.
The Motley Fool November 27, 2006 Brian Lawler	Roche Says Goodbye to PDL The larger pharmaceutical drops out of daclizumab development. Investors, take note.
The Motley Fool June 7, 2011 Brian Orelli	Sometimes a Partnership Feels Personal Merck and Roche hook up for a diagnostic drug deal.
BusinessWeek July 1, 2010 Doherty & Waters	Post-Buyout, Genentech's DNA Is Dominant Bought out for $47 billion, the biotech pioneer has gained the upper hand
The Motley Fool August 22, 2007 Brian Orelli	Yes? No? Maybe So? Roche is still after Ventana. While longtime investors are happy that Roche pointed out Ventana's undervaluation to the rest of the world, current investors think Roche's offer is still too low.
Pharmaceutical Executive October 1, 2005 Mark J. Ahn	It's All Academic: Biotechs Looking to Universities Pharmaceuticals and academic institutions are forming alliances at an increasing rate to exploit the promise of emerging biological insights.
Fast Company January 2002 George Anders	Roche's New Scientific Method How does a giant pharmaceutical company reckon with genomics technology? By making a fresh start in how it recruits its scientists, manages projects, and uses computers. Here's how the Roche Group is reinventing how it invents...
The Motley Fool February 12, 2010 Brian Orelli	Don't Ignore This Potential Blockbuster Five trials later, Roche's diabetes drug taspoglutide seems like a winner.
Chemistry World August 6, 2013 Phillip Broadwith	Antiviral patents released by Roche A five-year agreement between Roche and Unitaid's Medicines Patent Pool will make more antiviral drugs available at knock-down prices in developing countries.
BusinessWeek October 1, 2007 Conrad Wilson	A Dream Team Of Drugs And Diagnosis? If a deal is struck, a Roche-Ventana team could help launch a medical revolution.
The Motley Fool June 30, 2011 Brian Orelli	2 Backdoor Biotech IPOs to Watch Just don't buy yet.
BusinessWeek November 24, 2003 John Carey	Barring The Door Against AIDS A new generation of drugs focuses on keeping the virus from entering cells.
The Motley Fool December 11, 2009 Brian Orelli	Roche and Biogen's Blockbuster Making Good Progress Roche and Biogen move their potential blockbuster through the clinical trial maze.
The Motley Fool July 20, 2004 Brian Gorman	Bayer Reshuffles Business Bayer, one of Germany's most venerable industrial names, is revamping its house. Seemingly in one fell swoop, the company is spinning off its Lanxess chemicals and polymers unit and buying Roche's over-the-counter-drugs business.
Chemistry World October 29, 2014 Phillip Broadwith	CHF3bn redevelopment for Roche's Basel site Swiss pharma major Roche plans to spend CHF3 billion ( 2 billion pounds) over the next 10 years on redeveloping its headquarters in Basel.
The Motley Fool January 29, 2008 Brian Lawler	Genentech Adds to Avastin's Arsenal Genentech's lead drug Avastin gains another use -- just not the one investors expected.
The Motley Fool June 21, 2011 Brian Orelli	Data Look Good, Approval Unknown Accelerated approvals are like that. The data should give Curis' investors added confidence that vismodegib works, but whether it can get approved with this limited data remains to be seen.
The Motley Fool January 6, 2012 Brian Orelli	Don't Read Too Much Into This Partnership While the partnership is not a sign that Roche will buy Aeterna Zentaris, there's no doubt that the development of AEZS-108 makes the biotech a more attractive takeout candidate.
The Motley Fool December 11, 2006 Brian Lawler	Roche's Early Present to Halozyme Assuming it works, Enhanze may be a platform technology that could be applied across a wide range of injected products. Roche isn't exactly betting the farm on its success, though, with only $20 million of guaranteed up-front money. Investors, take note.
The Motley Fool May 2, 2007 Brian Lawler	Progenics' Intriguing Study Results The development-stage drugmaker released clinical trial results for one of its compounds. Investors, take note.
Chemistry World February 26, 2014 Ned Stafford	Roche disputes unethical East German trial claims Clinical trials in the 1980s, performed in former communist East Germany by global pharmaceutical giant Hoffmann-La Roche, adhered to international standards and did not violate East German laws, according to a report issued by the company after a six month internal investigation.
The Motley Fool July 16, 2007 Brian Orelli	Ventana Says No, We Can't Talk In many ways, Ventana is actually a perfect match for Roche. But for now, this hostile takeover bid is stalled. Investors, take note.
Geotimes December 2004 Megan Sever	Alaska's New Pipeline For close to 30 years, people have been working to build a natural gas pipeline from Alaska's North Slope to the lower 48 states. In October, Congress finally gave the go-ahead by authorizing the construction of the pipeline.